A new umbrella review reveals how GLP-1 therapies shape cardiovascular, renal, and metabolic outcomes in type 2 diabetes while highlighting drug-specific advantages and the need to manage ...

GLP-1RA use improves major cardiovascular and kidney outcomes among patients with systemic lupus erythematosus and lupus nephritis. Use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) is ...

Some dietary supplements may help naturally boost GLP-1, but more research is needed to better understand their potential ...

SGLT-2 inhibitor and GLP-1 receptor agonist drugs should be used in all or almost all adults with type 2 diabetes at higher risk of cardiovascular and kidney complications, and in the majority of ...

Patients with lupus and type 2 diabetes are predisposed to a disproportionate risk of atherosclerotic cardiovascular disease and chronic kidney disease. A study of this patient population showed that ...

The resulting study, published in the medical journal JAMA Network Open, looked at the health data of 21,790 veterans with type 2 diabetes to compare three different GLP-1 RAs - liraglutide, ...

Please provide your email address to receive an email when new articles are posted on . Use of GLP-1 drugs was linked to a 23% lower mortality risk for adults with type 2 diabetes on dialysis. The ...

GLP-1 medicines have been utilised for the treatment of diabetes; however, they are now emerging as important topics for the treatment of obesity ...

Dr. Angela Fitch, co-founder and chief medical officer of knownwell, a "weight-inclusive" healthcare company based in Boston, said she would caution against labeling any medication as an "everything ...

SGLT-2 inhibitor and GLP-1 receptor agonist drugs should be used in all or almost all adults with type 2 diabetes at higher risk of cardiovascular and kidney complications, and in the majority of ...